Nevro (NYSE:NVRO)‘s stock had its “hold” rating reaffirmed by research analysts at Northland Securities in a research report issued on Friday. They presently have a $48.00 target price on the medical equipment provider’s stock. Northland Securities’ price target would indicate a potential upside of 21.61% from the stock’s previous close.

The analysts wrote, “We are introducing our FY20 numbers, and our rating / PT remains the same.””

Several other equities analysts also recently commented on NVRO. Zacks Investment Research downgraded Nevro from a “buy” rating to a “hold” rating in a research note on Thursday. Canaccord Genuity dropped their price objective on Nevro from $80.00 to $63.00 and set an “in-line” rating on the stock in a research note on Tuesday, November 6th. They noted that the move was a valuation call. Wells Fargo & Co dropped their price objective on Nevro from $62.00 to $50.00 and set a “market perform” rating on the stock in a research note on Tuesday, November 6th. UBS Group assumed coverage on Nevro in a research note on Tuesday, November 27th. They issued a “sell” rating and a $35.00 price objective on the stock. Finally, BMO Capital Markets dropped their target price on Nevro from $76.00 to $60.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 6th. They noted that the move was a valuation call. Four research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $58.00.

Nevro stock traded down $0.89 during trading on Friday, hitting $39.47. The stock had a trading volume of 16,905 shares, compared to its average volume of 633,626. Nevro has a 1 year low of $34.75 and a 1 year high of $94.34. The company has a current ratio of 8.05, a quick ratio of 6.31 and a debt-to-equity ratio of 0.62. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -31.58 and a beta of -0.12.

Nevro (NYSE:NVRO) last posted its quarterly earnings data on Monday, November 5th. The medical equipment provider reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Nevro had a negative net margin of 11.64% and a negative return on equity of 17.89%. The firm had revenue of $95.60 million during the quarter, compared to analysts’ expectations of $94.29 million. During the same quarter in the previous year, the company posted ($0.21) EPS. Nevro’s revenue for the quarter was up 16.2% on a year-over-year basis. As a group, equities research analysts forecast that Nevro will post -1.49 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the business. Cerebellum GP LLC bought a new position in shares of Nevro in the fourth quarter worth $177,000. Vanguard Group Inc increased its holdings in shares of Nevro by 6.7% in the third quarter. Vanguard Group Inc now owns 2,518,566 shares of the medical equipment provider’s stock worth $143,558,000 after purchasing an additional 158,826 shares during the period. Federated Investors Inc. PA increased its holdings in shares of Nevro by 58.2% in the third quarter. Federated Investors Inc. PA now owns 489,108 shares of the medical equipment provider’s stock worth $27,879,000 after purchasing an additional 180,008 shares during the period. Marshall Wace LLP bought a new position in shares of Nevro in the third quarter worth $1,711,000. Finally, Vanguard Group Inc. increased its holdings in shares of Nevro by 6.7% in the third quarter. Vanguard Group Inc. now owns 2,518,566 shares of the medical equipment provider’s stock worth $143,558,000 after purchasing an additional 158,826 shares during the period.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Story: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.